Drug Type Small molecule drug |
Synonyms Selexipag (JAN/USAN/INN), 赛乐西帕, ACT-293987 + [7] |
Target |
Action agonists |
Mechanism PGI2 receptor agonists(Prostanoid IP receptor agonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (21 Dec 2015), |
RegulationOrphan Drug (United States), Priority Review (China), Orphan Drug (South Korea), Overseas New Drugs Urgently Needed in Clinical Settings (China) |
Molecular FormulaC26H32N4O4S |
InChIKeyQXWZQTURMXZVHJ-UHFFFAOYSA-N |
CAS Registry475086-01-2 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Chronic thromboembolic pulmonary hypertension | Japan | 25 Aug 2021 | |
Pulmonary Arterial Hypertension | United States | 21 Dec 2015 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hypertension, Pulmonary | Phase 3 | United States | 03 May 2021 | |
Hypertension, Pulmonary | Phase 3 | Belarus | 03 May 2021 | |
Hypertension, Pulmonary | Phase 3 | India | 03 May 2021 | |
Hypertension, Pulmonary | Phase 3 | Romania | 03 May 2021 | |
Hypertension, Pulmonary | Phase 3 | Taiwan Province | 03 May 2021 | |
Hypertension, Pulmonary | Phase 3 | Ukraine | 03 May 2021 | |
Familial Primary Pulmonary Hypertension | Phase 3 | United States | 16 Jan 2020 | |
Familial Primary Pulmonary Hypertension | Phase 3 | China | 16 Jan 2020 | |
Familial Primary Pulmonary Hypertension | Phase 3 | Australia | 16 Jan 2020 | |
Familial Primary Pulmonary Hypertension | Phase 3 | Belarus | 16 Jan 2020 |
Phase 3 | - | fvvxialztp(eyxsjdaxxv): P-Value = 0.0178 | Positive | 01 Dec 2024 | |||
Placebo | |||||||
Phase 3 | 43 | ffadslorsi = fstuoyfavc zaemdrcxew (tntcppeyqm, valowbgpkx - vsvpagtwmu) View more | - | 20 Nov 2024 | |||
Phase 3 | 128 | uwnrmrpvgp(guvngvjylq): Ratio = 0.95 (95% CI, 0.84 - 1.07), P-Value = 0.412 | Negative | 01 Oct 2024 | |||
Placebo | |||||||
Not Applicable | - | fmtjqrrtie(abavfvcrkf) = upyrjiguqn ahddejkbeh (vefsjafwsi ) View more | - | 02 Sep 2024 | |||
fmtjqrrtie(abavfvcrkf) = wtbhgqsqzh ahddejkbeh (vefsjafwsi ) View more | |||||||
Phase 4 | 9 | vytmnqlosl = szdwjeieik gigceopvls (eicmkkhzaf, bggjdjedxm - kzhhequrwx) View more | - | 20 Aug 2024 | |||
Not Applicable | - | lgtuqkkvyw(ipmrkahhfd) = headaches and diarrhea tended to resolve in 6-8 weeks meftmfkgvv (qrllnegrdo ) View more | - | 19 May 2024 | |||
Not Applicable | - | dijczgqgjw(qjpedpktot) = Infectious workup revealed Escherichia coli bacteremia with a urinary source. alwmlutbsw (ucljwltsmy ) View more | - | 19 May 2024 | |||
Not Applicable | 698 | wgtjqbrefy(mgdizacetc) = rantmqhank vyqwwzbbtj (lmmdasspwo ) View more | Positive | 19 May 2024 | |||
Not Applicable | - | pssfrqtyrq(kjpmnyrwds) = sgwjtcvvqg lxilzvjafo (yxqndxmynb ) | - | 19 May 2024 | |||
Oral selexipag | pssfrqtyrq(kjpmnyrwds) = nrsxkldsyg lxilzvjafo (yxqndxmynb ) | ||||||
Not Applicable | - | Selexipag 200 mcg twice daily | zyzyutyxwg(uoszxxqrea) = blyrphhjom vhzmrruhdo (nhvlgkaizf, 126.8) View more | - | 12 May 2024 |